Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip

Executive Summary

Amgen reported reduced revenue for 2017 and its 2018 guidance anticipates either flat sales or further decline, so the company is under increasing pressure to spend its $41.7bn in cash in ways that boost earnings, but $14.4bn already is committed to buying stock back from shareholders.


Related Content

As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study
First Biosimilar Neulasta In Final Stages Of EMA Review Process
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Mylan Insists Complex Generics Strategy Is Poised To Deliver
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance
Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts